Background: Ganciclovir and valganciclovir are used for prophylaxis and treatment of
cytomegalovirus infection. However, there is great interindividual variability in ganciclovir's …

Population pharmacokinetic (PopPK) and physiologically based pharmacokinetic (PBPK)
models are frequently used to support pediatric drug development. Both methods have …

A physiologically based pharmacokinetic (PBPK) model has been developed for ganciclovir
and its prodrug valganciclovir. Initial bottom-up modeling based on physicochemical drug …

Intravenous ganciclovir and oral valganciclovir are effective in the prevention and treatment
of pediatric cytomegalovirus (CMV) infection but various dosing regimens are used in …

Objective: To develop a population pharmacokinetic model for valganciclovir in paediatric
renal transplant recipients, identify covariates that explain variability, and determine …

Ganciclovir is indicated for curative or preventive treatment of cytomegalovirus (CMV)
infections. This study aimed to characterize ganciclovir pharmacokinetics, following …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Famciclovir is licensed in adults for
the treatment of herpes zoster and herpes simplex viral infections.• The pharmacokinetics of …

Introduction: Among infants and immunocompromised children cytomegalovirus (CMV) is
associated with significant morbidity and mortality. Areas covered: This review describes the …

Abstract Background and Objectives Ganciclovir (GCV) and valganciclovir (VGCV) show
large interindividual pharmacokinetic variability, particularly in children. The objectives of …

Aims Ganciclovir (GCV) and its prodrug valganciclovir (VGCV) are first‐line agents to
prevent and treat cytomegalovirus in transplant recipients. There is high pharmacokinetic …